Artificial intelligence is being increasingly integrated into preclinical drug studies to improve operational efficiency, according to Dr. Steven Bulera, global head of toxicology at Charles River Laboratories. While AI tools offer significant potential to accelerate the transition from drug concept to evaluation, scientific and regulatory limitations remain. Preclinical studies represent a critical stage in drug development requiring substantial time, investment, and ethical commitment before human trials can begin.
Quwwaa is your AI news butler — a personalized brief and assistant for the stories you care about.
See more on Quwwaa — create a free account